Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S, Dammeijer F, Hendriks RW. Pal Singh S, et al. Among authors: dammeijer f. Mol Cancer. 2018 Feb 19;17(1):57. doi: 10.1186/s12943-018-0779-z. Mol Cancer. 2018. PMID: 29455639 Free PMC article. Review.
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
Lau SP, van Montfoort N, Kinderman P, Lukkes M, Klaase L, van Nimwegen M, van Gulijk M, Dumas J, Mustafa DAM, Lievense SLA, Groeneveldt C, Stadhouders R, Li Y, Stubbs A, Marijt KA, Vroman H, van der Burg SH, Aerts J, van Hall T, Dammeijer F, van Eijck CHJ. Lau SP, et al. Among authors: dammeijer f. J Immunother Cancer. 2020 Jul;8(2):e000772. doi: 10.1136/jitc-2020-000772. J Immunother Cancer. 2020. PMID: 32690771 Free PMC article.
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP, Latupeirissa K, Schetters S, van Kooyk Y, Boon L, Moyaart A, Mueller YM, Katsikis PD, Eggermont AM, Vroman H, Stadhouders R, Hendriks RW, Thüsen JV, Grünhagen DJ, Verhoef C, van Hall T, Aerts JG. Dammeijer F, et al. Cancer Cell. 2020 Nov 9;38(5):685-700.e8. doi: 10.1016/j.ccell.2020.09.001. Epub 2020 Oct 1. Cancer Cell. 2020. PMID: 33007259 Free article.
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
de Gooijer CJ, van der Noort V, Stigt JA, Baas P, Biesma B, Cornelissen R, van Walree N, van Heemst RC, Soud MY, Groen HJM, den Brekel AJS, Buikhuisen WA, Bootsma GP, Dammeijer F, van Tinteren H, Lalezari F, Aerts JG, Burgers JA; NVALT19 study group. de Gooijer CJ, et al. Among authors: dammeijer f. Lancet Respir Med. 2021 Jun;9(6):585-592. doi: 10.1016/S2213-2600(20)30362-3. Epub 2021 Jan 27. Lancet Respir Med. 2021. PMID: 33515500 Clinical Trial.
16 results